The Filing Desk

Celldex Therapeutics vs Inhibrx Biosciences

Celldex Therapeutics CLDX · Inhibrx Biosciences INBX · Biotechnology

Celldex Therapeutics reported revenue of $2 million in fiscal 2025, 1.2 times Inhibrx Biosciences' $1 million in fiscal 2025. Celldex Therapeutics' revenue fell 78.0% in its latest year, and Inhibrx Biosciences' grew 550.0%. Celldex Therapeutics had an operating margin of -18599.8%, against -10386.5% at Inhibrx Biosciences. Free cash flow was −$214 million at Celldex Therapeutics and −$130 million at Inhibrx Biosciences.

Side by side

Celldex TherapeuticsInhibrx Biosciences
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$2M$1M
Revenue growth−78.0%550.0%
Revenue growth a year, last 5 years−27.3%—
Gross margin87.1%—
Operating margin−18,599.8%−10,386.5%
Net margin−16,748.0%−10,773.5%
Free cash flow−$214M−$130M
Free cash flow margin−13,829.1%−9,986.5%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count3.1%3.4%
Last close$28.83$83.30
P/E at the last close——
Insider trades, last 12 monthssold $121,231—
Piotroski F-score—2 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Celldex TherapeuticsInhibrx Biosciences
Operating margin
Percent of revenue
Celldex TherapeuticsInhibrx Biosciences
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Celldex TherapeuticsInhibrx Biosciences

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Celldex Therapeutics and Inhibrx Biosciences pages.